Valneva SE - Asset Resilience Ratio
Valneva SE (VLA) has an Asset Resilience Ratio of 0.03% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check VLA capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2014)
This chart shows how Valneva SE's Asset Resilience Ratio has changed over time. See Valneva SE (VLA) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Valneva SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Valneva SE worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €150.00K | 0.03% |
| Total Liquid Assets | €150.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Valneva SE maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Valneva SE Industry Peers by Asset Resilience Ratio
Compare Valneva SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Valneva SE (2005–2014)
The table below shows the annual Asset Resilience Ratio data for Valneva SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2014-12-31 | 0.01% | €19.00K ≈ $22.21K |
€227.52 Million ≈ $265.99 Million |
-1.43pp |
| 2013-12-31 | 1.44% | €3.66 Million ≈ $4.28 Million |
€254.39 Million ≈ $297.41 Million |
-19.48pp |
| 2012-12-31 | 20.92% | €11.22 Million ≈ $13.12 Million |
€53.67 Million ≈ $62.74 Million |
-7.34pp |
| 2011-12-31 | 28.25% | €20.65 Million ≈ $24.14 Million |
€73.08 Million ≈ $85.44 Million |
+18.50pp |
| 2010-12-31 | 9.75% | €7.75 Million ≈ $9.07 Million |
€79.50 Million ≈ $92.94 Million |
+0.06pp |
| 2008-12-31 | 9.70% | €4.01 Million ≈ $4.69 Million |
€41.38 Million ≈ $48.38 Million |
-19.50pp |
| 2007-12-31 | 29.20% | €11.56 Million ≈ $13.51 Million |
€39.58 Million ≈ $46.28 Million |
+17.93pp |
| 2006-12-31 | 11.27% | €1.68 Million ≈ $1.97 Million |
€14.92 Million ≈ $17.45 Million |
-11.83pp |
| 2005-12-31 | 23.10% | €3.37 Million ≈ $3.94 Million |
€14.60 Million ≈ $17.07 Million |
-- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more